Share this story:

nDatalyze Corp. ("NDAT" or the "Corporation") (CSE:NDAT) (OTC:NDATF) advances its Clinical Study process

nDatalyze Corp.

Calgary, Alberta – TheNewswire - September 21, 2023nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) announces that it has received multiple expressions of interest from highly-qualified potential Principal Investigators (“PI”) for its previously-announced, Mitacs-sponsored Clinical Study. The potential PIs to date include qualified persons in the fields of Psychiatry and AI/Machine-Learning. The Clinical Study is being undertaken to test, calibrate and validate the machine-learning based, YMI Clinical Decision Support System (“CDSS”) and will be funded in combination with Mitacs. Mitacs typically shares costs, but the ratio cannot be known until the PI sets out the process, protocols, and budget. Details will be released once the Clinical Study is formalized. Interested parties can view the project outline at YMI is currently a fully operational online system based on the Corporation’s proprietary Reference Database and Machine-Learning algorithms. Those who wish to try the system at no charge are urged to contact


James Durward, President, states “It’s wonderful to experience the excitement of these highly qualified experts and I look forward to working with the selected parties during the Clinical Study. In my opinion, machine-learning has the potential to fundamentally change the way mental conditions are diagnosed and treated; promising a significant reduction of mis/overdiagnoses and attendant follow-on mis/overprescriptions that contribute to the clogged mental health system. The recent groundswell supporting proactive mental health reinforces our decision to focus on making YMI available to the medical community as soon as practically possible.”


The Corporation firmly believes that NDATs extremely low capitalization compared to its peers presents an outstanding investment opportunity for those investors active in the mental health space. Some peer examples:




Market Cap

Products/ Services

Recent Activities



$295mm (US$)

●Online therapy
●Couples therapy
●Teen therapy

launched Talkspace, a product providing a number of offerings that helps teams, executives and managers to build mental wellness and emotional quotient. Large revenues




$13mm (CAD)

●predictive health-related conditions

Looking for partners and financing – no revenue




$21mm (CAD)

●AI-assisted Clinical trial efficiency software designed to increase clinical trial success rate

Multiple financings to support research and G&A expenses. Minimal revenue





● offers innovative tools designed to deliver evidence-based best practices to clinicians

Announced that its Pharmapod system was selected by an Ontario long-term care chain. Significant revenues and multiple debt financings.



$ 3mm (CAD)

●YMI mental health Clinical Decision Support System

nDatalyze finalized the supervised ML algorithms for seven mental health conditions (personality disorder, anxiety, alcoholism, post-traumatic stress disorder (PTSD), bipolar disorder, obsessive-compulsive disorder (OCD) and depression) and completed ML testing. Minimal revenue. Currently arranging a Clinical Study to refine, calibrate and validate the system.


About YMI: YMI uses evidence-based, objective data from whole life experiences to predict individual mental states over time and applies this knowledge towards a fuller understanding of how mental health develops and to improve mental wellbeing. YMI combines machine-learning with a proprietary Reference Database that contains >1200 person’s genetic expressions, childhood environment, habits, phobias, lived experiences and lifestyle to generate a personalized graphic report predicting an individual’s predisposition toward a variety of common mental conditions, both current and forward in time.


For Further Information, Please Contact:

James Durward, President and CEO

Telephone: (403) 689-3901


nDatalyze Website:      

YMI Website:


Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.


The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.